Allergan Aesthetics has secured EU approval for Boey (trenibotulinumtoxinE), positioning it as the first and only rapid-onset, short-duration neurotoxin for temporary glabellar frown-line improvement in adults. The product differentiates itself through faster onset—results appearing within days rather than the typical 7–14 days for botulinum toxin type A—and shorter duration, making it a distinct clinical profile within the neuromodulator category.
AbbVie's Boey Wins EU Approval for Frown Lines — First Rapid-Onset Botox Alternative
Allergan Aesthetics' trenibotulinumtoxinE gains European clearance as a faster-acting, shorter-duration neuromodulator.

| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
First and only rapid-onset, short-duration neurotoxin for frown lines in Europe.
For medspa owners, Boey represents new competitive pressure in the toxin market. While AbbVie maintains dominance through Botox and Dysport, this entry signals intent to capture patients seeking quicker results and shorter commitment windows. The mechanism—a different botulinum toxin serotype—carries different diffusion and unit-to-effect ratios, requiring practice retraining and potentially new pricing strategies. EU approval is the regulatory foothold; US FDA clearance remains the material gate for North American practices.
Source: original report ↗
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.